Anlotinib is a TKI targeting vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet derived growth factor receptor (PDGFR), stem cell factor receptor (c-Kit), and Ret (52), and is used in the treatment of advanced non-small cell lung cancer (NSCLC) (53). This evidence concerns the gene PDGFRB and non-small cell lung carcinoma.